Incyte Corp Files Amendment to Annual Report

TL;DR

<b>Incyte Corporation has filed an amendment to its 2023 annual report, providing updated information.</b>

AI Summary

INCYTE CORP (INCY) filed a Amended Annual Report (10-K/A) with the SEC on February 16, 2024. Incyte Corporation filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The filing was made on February 16, 2024. The company's principal executive offices are located at 1801 Augustine Cut-Off, Wilmington, DE 19803. Incyte Corporation is registered in Delaware and has an IRS Employer Identification No. of 94-3136539. The company's common stock is traded on The Nasdaq Stock Market LLC under the symbol INCY.

Why It Matters

For investors and stakeholders tracking INCYTE CORP, this filing contains several important signals. This amendment indicates that Incyte Corporation is providing updated or corrected information for its 2023 fiscal year, which could impact investor understanding of its financial and operational status. As a publicly traded company, timely and accurate filings with the SEC are crucial for maintaining investor confidence and regulatory compliance.

Risk Assessment

Risk Level: low — INCYTE CORP shows low risk based on this filing. The filing is an amendment to a standard annual report, suggesting no immediate new material risks have emerged, but rather a correction or update to existing disclosures.

Analyst Insight

Investors should review the specific changes made in this amendment to understand any updated disclosures or corrections to the company's 2023 financial performance or business operations.

Key Numbers

• 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 2024-02-16 — Filing Date (Filed as of date)
• 001-12400 — Commission File Number (SEC File Number)
• 94-3136539 — IRS Employer Identification No. (IRS Number)

Key Players & Entities

• Incyte Corporation (company) — Registrant name
• 0000879169-24-000062 (other) — Accession Number
• 20231231 (date) — Fiscal year end
• 20240216 (date) — Filing date
• 1801 Augustine Cut-Off, Wilmington, DE 19803 (address) — Business address
• INCY (ticker) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• Delaware (jurisdiction) — State of incorporation

FAQ

Industry Context

Incyte Corporation operates in the commercial physical & biological research sector, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information to investors.

What Investors Should Do

1. Review the specific amendments made in the 10-K/A filing for any changes to financial statements or business disclosures.
2. Monitor future filings for any new information or updates related to Incyte Corporation's operations and financial health.
3. Verify the accuracy of corporate and financial data presented in the amendment.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the annual report.
• 2024-02-16: Filing Date — Date the amendment was filed with the SEC.

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previously filed annual report for the fiscal year ended December 31, 2023, indicating updates or corrections rather than a new filing.

Filing Documents

• incy-20231231.htm (10-K/A) — 94KB
• incy-202310xkxaxex313.htm (EX-31.3) — 4KB
• incy-202310xkxaxex314.htm (EX-31.4) — 4KB
• incytepolicyforrecoupmento.htm (EX-97.1) — 29KB
• 0000879169-24-000062.txt (&nbsp;) — 352KB
• incy-20231231.xsd (EX-101.SCH) — 2KB
• incy-20231231_lab.xml (EX-101.LAB) — 40KB
• incy-20231231_pre.xml (EX-101.PRE) — 21KB
• incy-20231231_htm.xml (XML) — 6KB

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules (a) Documents filed as part of this report: (1) Financial Statements Reference is made to the Index to Consolidated Financial Statements of Incyte Corporation under Item 8 of Part II hereof. (2) Financial Statement Schedules All financial statement schedules have been omitted because they are not applicable or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto. (3) Exhibits See Item 15(b) below. Each management contract or compensatory plan or arrangement required to be filed has been identified. (b) Exhibits Exhibit Number Description of Document 3(i) Integrated copy of the Restated Certificate of Incorporation, as amended, of the Company (incorporated by reference to Exhibit 3(i) to the Company's Annual Report on Form 10-K for the year ended December 31, 2009). 3(ii) Bylaws of the Company, as amended as of July 27, 2023 (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023). 4.1 Form of Common Stock Certificate (incorporated by reference to the Exhibit 4.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2002). 4.2 Description of Registrant's Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019). 1 Exhibit Number Description of Document 10.1# Incyte Corporation Amended and Restated 2010 Stock Incentive Plan, as amended on April 13, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 15, 2023). 10.2# Form of Global Stock Option Agreement for Executive Officers under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment to be signed on its behalf by the undersigned, thereunto duly authorized. INCYTE CORPORATION By: /s/ H ERV H OPPENOT Herv Hoppenot President and Chief Executive Officer Date: February 16, 2024 4

View Full Filing

View this 10-K/A filing on SEC EDGAR